home / stock / athe / athe articles

ATHE Articles, Alterity Therapeutics Limited - From 07/18/24

Stock Information
Company Name: Alterity Therapeutics Limited
Stock Symbol: ATHE
Market: NYSE
Website: alteritytherapeutics.com
Menu
ATHE ATHE Quote ATHE Short ATHE News ATHE Articles ATHE Message Board
Get ATHE Alerts

News, Short Squeeze, Breakout and More Instantly...
Alterity Up on Interim Data From Advance MSA Study | Benzinga

Shares of Alterity Therapeutics (NASDAQ: ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-20...
Alterity Therapeutics to Present at the MST Access 'Hidden Gems in Life Sciences' Webinar | Benzinga

MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Com...

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study | Benzinga

- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt Universi...

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting | Benzinga

– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson's Disease – – ATH434-201 Phase 2 Baseline Data...
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session | Benzinga

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the P...

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 | Benzinga

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Co...

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund | Benzinga

MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited ((ASX: ATH, NASDAQ:ATHE) ("Alterity" ...
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting | Benzinga

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease to be Presented at International Conference – – Baseline ...

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week | Benzinga

MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Com...

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer | Benzinga

MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Com...
Previous 10 Next 10